The successful commercialization of drug-eluting stents (DES) has done much to pave the way for the biocoating industy. DES not only helped establish a new regulatory body to facilitate device-drug reviews, the FDA Office of Combination Products, they also proved that biocoated devices could take market share from uncoated products, command premium pricing and premium reimbursement.

Diagnostic Imaging; Breast Cancer. TransScan Medical is developing a new diagnostic modality that it will initially market to radiologists as an adjunct to mammography. The company's technology is based on the electrical impedance properties of tissue.